Loading
Life sciences · Journal article
Acs Sensors · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Monitoring therapy-induced molecular changes within subcellular compartments is crucial for understanding cellular stress and providing clues to treatment response. Mitochondrial base excision repair (BER) enzymes have emerged as promising indicators of therapeutic response, yet effective tools for their on-site and dynamic monitoring remain scarce. Here, we report an endogenously gated DNA nanodevice (EGDN) capable of real-time, mitochondria-specific monitoring of flap endonuclease 1 (FEN1), a key BER enzyme, under therapeutic challenge. The EGDN remains silent during transport and is sequentially activated by the mitochondria-encoded ribosomal RNA and FEN1, thus achieving spatial control over FEN1 imaging. This conditional regulation pattern reduces nonspecific signals and sharpens the spatial resolution of FEN1 visualization within mitochondria. We further demonstrate that EGDN dynamically tracks mitochondrial FEN1 fluctuations in tumor cells undergoing chemotherapy or radiation therapy, providing a molecular readout of treatment-associated alterations. Collectively, this work establishes a robust biosensing toolbox for dissecting the BER process at the subcellular level, with broad implications for cancer early diagnosis and targeted therapy.